FOXO4-DRI prices

FROM PEPTIDES CALCULATOR

About FOXO4-DRI

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

FOXO4-DRI is a synthetic 46-amino-acid peptide built from D-amino acids in a retro-inverso arrangement, pairing a fragment of the FOXO4 forkhead domain with an HIV-TAT cell-penetrating tail so that it resists proteases and enters cells. It was designed by Peter de Keizer's group at Erasmus MC and described in Cell in 2017 as a senolytic: it blocks the FOXO4 to p53 interaction that keeps senescent cells alive, freeing p53 to trigger apoptosis in those cells. Every efficacy result comes from mouse models (chemotherapy-induced senescence, fast-aging XpdTTD/TTD mice, naturally aged mice, aged testes, bleomycin lung fibrosis, vascular aging) and from cell culture. No human trial has been registered or published, no regulator has approved it, and the spin-out Cleara Biotech has moved on to next-generation candidates, so the compound sold online (sometimes as Proxofim) is an unregulated research chemical with no human dose, safety or pharmacokinetic data.

Formula

C228 H388 N86 O64

Molar mass

5,358 g/mol

CAS number

2460055-10-9

Amino acids

46

Research evidence described in the source

Limitations noted in the source

• Individual claims and source links have not yet completed editorial verification.
• Evidence level, applicable study model, formulation, route and population remain unassigned.

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.